Summary of recommendations and good practice points

Section 1: Introduction

Section 2: Methodology

Section 3: Epidemiology of NTM-pulmonary disease

Section 4: What is the evidence for transmission of NTM between individuals?

Section 5: How should the lung disease attributable to NTM infection be defined?

Section 6: What samples should be used to detect NTM infection?

Section 7: What microbiological tests should be used to detect NTM in respiratory samples?

Section 8: What microbiological tests should be used to speciate and type NTM from respiratory samples?

Section 9: Does in vitro DST predict response to antibiotic treatment in people with NTM-pulmonary infection?

Section 10: What investigations should be performed in individuals suspected of having NTM-pulmonary disease?

Section 11: What factors influence when NTM treatment should be started?
Section 12: What antibiotic regimen should be used to treat NTM-PD?

Section 12a: What antibiotic regimen should be used to treat MAC-pulmonary disease?

Section 12b: What antibiotic regimen should be used to treat *M. kansasii*-pulmonary disease?

Section 12c: What antibiotic regimen should be used to treat *M. malmoense*-pulmonary disease?

Section 12d: What antibiotic regimen should be used to treat *M. xenopi*-pulmonary disease?

Section 12e: What antibiotic regimen should be used to treat *M. abscessus*-pulmonary disease?

Section 13: Is there a role for adjuvant therapies in the management of NTM-pulmonary disease?

Section 14: What investigations should be performed during treatment or following treatment for NTM-pulmonary disease?

Section 15: Are there differences in outcome between individuals with NTM-pulmonary disease treated in specialist versus non-specialist care settings?

Section 16: What is the role of surgery in the treatment of NTM-pulmonary disease?

Section 17: Does NTM infection affect an individual’s suitability for lung transplantation?

Section 18: NTM drug monograph

Amikacin—intravenous
Amikacin—nebulised
Azithromycin
Bedaquiline
Cefoxitin
Ciprofloxacin
Clarithromycin
Clofazimine
Cotrimoxazole (trimethoprim/sulfamethoxazole)
Doxycycline
Ethambutol
Imipenem
Isoniazid
Linezolid
Minocycline
Moxifloxacin
Rifabutin
<table>
<thead>
<tr>
<th>Contents</th>
<th>References</th>
<th>Online appendices</th>
</tr>
</thead>
<tbody>
<tr>
<td>ii53 Rifampicin</td>
<td></td>
<td>The below documents are available at:</td>
</tr>
<tr>
<td>ii57 Tigecycline</td>
<td></td>
<td>1. Clinical questions and literature search strategy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Evidence tables</td>
</tr>
<tr>
<td>Section 19: Research</td>
<td></td>
<td>3. Patient information</td>
</tr>
<tr>
<td>recommendations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ii58 NTM epidemiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ii58 NTM microbiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ii58 NTM treatment</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>